RxDoctor Payments Data

Vinod Miryala, MD

Cardiovascular Disease · The Villages, FLNPI 1891996880

Payments from drug & device makers

$7,025in general payments, 2019–2025

Across 378 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$715
  • Amgen$526
  • Novartis$457
  • Boston Scientific$453
  • AstraZeneca$401
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$398
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$6,92799%
  • Education$591%
  • Other$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,025 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,311,949
Medicare patients
1,720
Services billed
12,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban677$888,115
EntrestoSacubitril/Valsartan141$175,185
XareltoRivaroxaban110$171,649
Repatha SureclickEvolocumab85$92,562
MultaqDronedarone Hcl27$49,490
JardianceEmpagliflozin45$46,040
OzempicSemaglutide31$32,181
FarxigaDapagliflozin Propanediol17$22,524
BrilintaTicagrelor21$21,038
EdarbyclorAzilsartan Med/Chlorthalidone35$20,060
Repatha SyringeEvolocumab17$13,888
Rosuvastatin Calcium617$9,824
Ranolazine ErRanolazine79$8,318
Praluent PenAlirocumab13$7,885
Prasugrel Hcl38$6,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$715$888,115677 claims
NovartisEntresto$457$175,185141 claims
Johnson & JohnsonXarelto$373$171,649110 claims
Sanofi-aventis U.S. LLCMultaq$398$49,49027 claims
Boehringer IngelheimJardiance$317$46,04045 claims
AstraZenecaFarxiga, Brilinta$401$43,56238 claims
Novo NordiskOzempic$32$32,18131 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$11$20,06035 claims
Esperion Therapeutics, Inc.Nexletol$173$4,52011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →